This commentary from Bioanalysis focuses on the status of drug detection with metal nanoparticles as ultrasmall labels in colorimetric-based methods.
Browsing: drug development
Global leaders in life sciences and nonclinical drug development, Envigo (Huntingdon, UK) and LabCorp (NC, USA), have signed an innovative agreement in a bid to expand nonclinical drug development capabilities and create an independent research models provider.
In this editorial Yu Shrike Zhang (Harvard Medical School; MA, USA), a previous finalist of the Bioanalysis Rising Star Award, discusses his research and hopes for the future. He details the emergence of organ-on-a-chip systems and how these platforms reproduce tissue functions outside the human body.
As part of our focus, we present this podcast where we talk to Mark Savage who discusses how software tools can address certain challenges and bring forward compounds from discovery to development.
The future of individualized medicine: intensified decentralized biotherapeutic production in combination with state-of-the-art diagnostics of the next generation
In this editorial the future of individualized medicine is reviewed, focusing on the decentralization of biotherapeutic production in combination with state-of-the-art diagnostics of the next generation.
In this interview, John Kellie (GSK, PA, USA) discusses the technologies that he uses on a regular basis. He explains how large molecule bioanalysis influences downstream drug development and his future outlook on where the field will be in 5–10 years’ time.
Quantitative whole body autoradiography (QWBA) and imaging mass spectrometry (IMS): can IMS replace QWBA to support regulated drug discovery and development
Read time: 4:45 mins
Eric Solon (Madrigal Pharmaceuticals; PA, USA) discusses whether or not IMS can replace QWBA as the technique of choice when examining the disposition of new drug and biotherapeutic entities.
In this installment of Robert MacNeill’s (Envigo) column, Robert discusses the instability of drugs within samples and how to balance their instability against absorptive loss.
For therapeutic drug development and monitoring, microsampling technology provides a breakthrough alternative
One useful way to think about volumetric absorptive microsampling (VAMS) technology is as the next generation of traditional dried blood spot (DBS) cards. It’s a simpler method that makes it easier to collect blood and prepare it for analysis. With minimal training, the microsampling process can be self-administered anywhere, through a procedure that is less difficult and generally less expensive than working with conventional venous blood. Other benefits include a more pleasant patient experience, which leads to greater adherence and compliance, and freer access to remote areas of the world.
The authors review the use of PBPK models to inform pediatric drug development and discuss the importance of considering the confidence in the predictions.